Coagulation, Fibrinolytic and Platelet Function in Patients on Long-Term Therapy with Aspirin 300 mg or 1200 mg Daily Compared with Placebo^[*]

Summary

Aspirin has been shown to be beneficial in the prophylaxis of arterial thromboembolic disease. The rationale for its use as an antithrombotic drug lies in its inhibition of thromboxane A₂- dependent platelet function. However, the effect of aspirin on coagulation and fibrinolysis during chronic therapy has not been studied. We have measured a range of haemostatic and platelet functions in 49 patients with transient ischaemic attacks randomly allocated to aspirin 300 mg a day, aspirin 1,200 mg a day or placebo. All had been taking their allocated treatment for between 9 months and 4 years prior to investigation. Bleeding time was prolonged, serum thromboxane diminished and platelet aggregation to arachidonic acid but not ADP was abolished by both 300 mg and 1,200 mg aspirin, in a non-dose dependent fashion. Serum salicylate increased with the dose of aspirin ingested. No effect was seen with either dose of aspirin on urinary thromboxane and 6-keto-PGF_1α excretion, or on coagulation. Patients taking 1,200 mg aspirin a day had a lower haemoglobin and packed cell volume, lower resting fibrinopeptide A concentration and lower basal plasminogen activator activity than those on placebo. Response to venous occlusion was norrnal in all groups. The results suggest 300 mg and 1,200 mg aspirin have an equivalent platelet inhibitory effect but 1,200 mg aspirin causes greater gastro-intestinal blood loss.

Dedicated to Professor Marc Verstraete on the occasion of his 65th birthday.

• References

• 1 Weiss HJ, Aledort LM. Impaired platelet connective-tissue reaction in man after aspirin ingestion. Lancet 1967; ii 495-497
• 2 UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316-320
• 3 Results of a Veterans Administration Cooperative Study. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396-403
• 4 Results of a Canadian Multicenter Trial. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369-1375
• 5 ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii 349-360
• 6 Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
• 7 Roth GJ, Siok CJ. Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 1978; 253: 3782-3784
• 8 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-3024
• 9 Villa S, de Gaetano G. Prostacyclin-like activity in rat vascular tissues. Fast, long-acting inhibition by treatment with lysine acetylsalicylate. Prostaglandins 1977; 14: 117-124
• 10 Moncada S, Vane JR. Arachidonic acid metabolites and interactions between platelets and blood-vessel wall. N Engl J Med 1979; 300: 1142-1147
• 11 FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
• 12 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1355-1372
• 13 Loew D, Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors. Haemostasis 1976; 5: 239-249
• 14 Moroz L. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296: 525-529
• 15 Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity in vivo. J Clin Invest 1984; 74: 571-580
• 16 de Gaetano G, Carriero MR, Cerletti C, Mussoni L. Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol 1986; 35: 3147-3150
• 17 de Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of platelet inhibition in humans: implication of the salicylate-aspirm interaction. Circulation 1985; 72: 1185-1193
• 18 Hardisty RM, MacPhearson JC. A one-stage FVIII AHG assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962; 7: 215-229
• 19 Woodhams BJ, Kemoff PB A. Rapid immunoassay for fibrinopep-tide A in human plasma. Thromb Res 1981; 22: 407-416
• 20 Nilsson IM, Hedner U, Pandolfi M. The measurement of fibrinolytic activities. In: Fibrinolytes and Antifibrinolytes Markwardt F. (ed). Springer Verlag; Berlin: 1978: 107-134
• 21 Marsh NA. Measurement of fibrinolytic capacity by the euglobulin lysis time method - a problem of “units”. Thromb Res 1977; 12: 197-200
• 22 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 23 Peng GW, Gadalla MA F, Smith V, Peng A, Chiou WL. Simple and rapid high-pressure liquid chromatographic simultaneous determination of aspirin, salicylic acid, and salcyluric acid in plasma. J Pharm Sci 1978; 67: 710-712
• 24 Bucchi F, Bodzenta A, de Gaetano G, Cerletti C. Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGFla in healthy subjects. Prostaglandins 1986; 32: 691-701
• 25 Miekle CH. Influence of aspirin on platelets and the bleeding time. Am J Med 1983; 74: 72-78
• 26 Frith PA, Warlow CP. A study of bleeding time in 120 long-term aspirin trial patients. Thromb Res 1988; 49: 463-470
• 27 Reilly AG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
• 28 Jones PB B, Russell RG G. Effect of aspirin on urinary excretion of 6-keto-prostaglandin Fla. Clin Sci 1983; 64: 395-398
• 29 Cattaneo M, D’Angelo A, Canciani MT, Asti D, Vigano-D’Angelo S, Tripodi A, Mannucci PM. Effect of oral aspirin on plasma levels of vitamin K-dependent clotting factors - studies in healthy volunteers. Thromb Haemostas 1988; 59: 540